A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)
A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks.
Inclusion Criteria:
Exclusion Criteria:
Phoenix, Arizona 85013, United States
Winston-Salem, North Carolina 27157, United States
Edmonton, Alberta T6G 2B7, Canada
Milan, Lombardy 20132, Italy
Turin, Piedmont 10126, Italy
Milan, 20162, Italy
Nagakute-shi, Aichi-ken 480-1195, Japan
Kita-gun, Kagawa-ken 761-0793, Japan
Koshi-shi, Kumamoto 861-1196, Japan
Toyonaka-shi, Osaka 560-8552, Japan
Shizuoka, Shizuoka 420-8688, Japan
Bunkyo-ku, Tokyo 113-8431, Japan